Phosphodiesterase type 5 inhibitor tadalafil reduces prostatic fibrosis via MiR-3126-3p/FGF9 axis in benign prostatic hyperplasia.
Male
Prostatic Hyperplasia
/ metabolism
MicroRNAs
/ genetics
Tadalafil
/ pharmacology
Phosphodiesterase 5 Inhibitors
/ pharmacology
Humans
Fibrosis
Fibroblast Growth Factor 9
/ metabolism
Prostate
/ drug effects
Myofibroblasts
/ metabolism
Transforming Growth Factor beta1
/ metabolism
Cell Proliferation
/ drug effects
Benign prostatic hyperplasia
FGF9
Myofibroblast differentiation
Phosphodiesterase 5 inhibitor
miR-3126-3p
Journal
Biology direct
ISSN: 1745-6150
Titre abrégé: Biol Direct
Pays: England
ID NLM: 101258412
Informations de publication
Date de publication:
02 Aug 2024
02 Aug 2024
Historique:
received:
14
03
2024
accepted:
19
07
2024
medline:
3
8
2024
pubmed:
3
8
2024
entrez:
2
8
2024
Statut:
epublish
Résumé
Myofibroblast buildup and prostatic fibrosis play a crucial role in the development of benign prostatic hyperplasia (BPH). Treatments specifically targeting myofibroblasts could be a promising approach for treating BPH. Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, holds the potential to intervene in this biological process. This study employs prostatic stromal fibroblasts to induce myofibroblast differentiation through TGFβ1 stimulation. As a result, tadalafil significantly inhibited prostatic stromal fibroblast proliferation and fibrosis process, compared to the control group. Furthermore, our transcriptome sequencing results revealed that tadalafil inhibited FGF9 secretion and simultaneously improved miR-3126-3p expression via TGFβ1 suppression. Overall, TGFβ1 can trigger pro-fibrotic signaling through miR-3126-3p in the prostatic stroma, and the use of tadalafil can inhibit this process.
Identifiants
pubmed: 39095835
doi: 10.1186/s13062-024-00504-y
pii: 10.1186/s13062-024-00504-y
doi:
Substances chimiques
MicroRNAs
0
Tadalafil
742SXX0ICT
Phosphodiesterase 5 Inhibitors
0
Fibroblast Growth Factor 9
0
FGF9 protein, human
0
Transforming Growth Factor beta1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
61Subventions
Organisme : Yangfan Plan of Shanghai Science and Technology Commission
ID : 20YF1438700
Organisme : National Natural Science Foundation of China
ID : 81870516
Informations de copyright
© 2024. The Author(s).
Références
Sarkar RR, Parsons JK, Bryant AK, Ryan ST, Kader AK, McKay RR, D’Amico AV, Nguyen PL, Hulley BJ, Einck JP, et al. Association of Treatment with 5alpha-Reductase inhibitors with time to diagnosis and mortality in prostate Cancer. JAMA Intern Med. 2019;179(6):812–9.
pubmed: 31058923
pmcid: 6503564
doi: 10.1001/jamainternmed.2019.0280
Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet. 2018;392(10159):1789–858.
doi: 10.1016/S0140-6736(18)32279-7
Madersbacher S, Sampson N, Culig Z. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: a Mini-review. Gerontology. 2019;65(5):458–64.
pubmed: 30943489
doi: 10.1159/000496289
Lokeshwar SD, Harper BT, Webb E, Jordan A, Dykes TA, Neal DE Jr., Terris MK, Klaassen Z. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol. 2019;8(5):529–39.
pubmed: 31807429
pmcid: 6842780
doi: 10.21037/tau.2019.10.01
Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, Te AE, Kaplan SA. Benign prostatic hyperplasia. Nat Rev Dis Primers. 2016;2:16031.
pubmed: 27147135
doi: 10.1038/nrdp.2016.31
Liu D, Shoag JE, Poliak D, Goueli RS, Ravikumar V, Redmond D, Vosoughi A, Fontugne J, Pan H, Lee D, et al. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nat Commun. 2020;11(1):1987.
pubmed: 32332823
pmcid: 7181734
doi: 10.1038/s41467-020-15913-6
Zhang B, Kwon OJ, Henry G, Malewska A, Wei X, Zhang L, Brinkley W, Zhang Y, Castro PD, Titus M, et al. Non-cell-autonomous regulation of prostate epithelial homeostasis by Androgen Receptor. Mol Cell. 2016;63(6):976–89.
pubmed: 27594448
pmcid: 5026614
doi: 10.1016/j.molcel.2016.07.025
Yang Y, Sheng J, Hu S, Cui Y, Xiao J, Yu W, Peng J, Han W, He Q, Fan Y, et al. Estrogen and G protein-coupled estrogen receptor accelerate the progression of benign prostatic hyperplasia by inducing prostatic fibrosis. Cell Death Dis. 2022;13(6):533.
pubmed: 35672281
pmcid: 9174491
doi: 10.1038/s41419-022-04979-3
Sheng J, Yang Y, Cui Y, He S, Wang L, Liu L, He Q, Lv T, Han W, Yu W, et al. M2 macrophage-mediated interleukin-4 signalling induces myofibroblast phenotype during the progression of benign prostatic hyperplasia. Cell Death Dis. 2018;9(7):755.
pubmed: 29988032
pmcid: 6037751
doi: 10.1038/s41419-018-0744-1
Sampson N, Zenzmaier C, Heitz M, Hermann M, Plas E, Schafer G, Klocker H, Berger P. Stromal insulin-like growth factor binding protein 3 (IGFBP3) is elevated in the diseased human prostate and promotes ex vivo fibroblast-to-myofibroblast differentiation. Endocrinology. 2013;154(8):2586–99.
pubmed: 23720424
doi: 10.1210/en.2012-2259
Hata J, Tanji R, Onagi A, Honda-Takinami R, Matsuoka K, Hoshi S, Sato Y, Akaihata H, Haga N, Kojima Y. Morphological change and characteristics of myofibroblasts during the growth process of benign prostatic hyperplasia. Int J Urol. 2020;27(8):676–83.
pubmed: 32476199
doi: 10.1111/iju.14265
Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, Gandhi MC, Kaplan SA, Kohler TS, Martin L, et al. Management of lower urinary tract symptoms attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial work-up and Medical Management. J Urol. 2021;206(4):806–17.
pubmed: 34384237
doi: 10.1097/JU.0000000000002183
Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F, Comb ATSG. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–31.
pubmed: 19825505
doi: 10.1016/j.eururo.2009.09.035
Andersson KE. PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery. Br J Pharmacol. 2018;175(13):2554–65.
pubmed: 29667180
pmcid: 6003652
doi: 10.1111/bph.14205
Fusco F, D’Anzeo G, Sessa A, Pace G, Rossi A, Capece M. d’Emmanuele Di Villa Bianca R: BPH/LUTS and ED: common pharmacological pathways for a common treatment. J Sex Med. 2013;10(10):2382–93.
pubmed: 23875757
doi: 10.1111/jsm.12261
Barnes H, Brown Z, Burns A, Williams T. Phosphodiesterase 5 inhibitors for pulmonary hypertension. Cochrane Database Syst Rev. 2019;1(1):CD012621.
pubmed: 30701543
Monica FZ, De Nucci G. Tadalafil for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother. 2019;20(8):929–37.
pubmed: 30901259
doi: 10.1080/14656566.2019.1589452
Ahmed WS, Geethakumari AM, Biswas KH. Phosphodiesterase 5 (PDE5): structure-function regulation and therapeutic applications of inhibitors. Biomed Pharmacother. 2021;134:111128.
pubmed: 33348311
doi: 10.1016/j.biopha.2020.111128
Park H, Park S, Kim KH, Cho MS, Sung SH, Ro JY. Stromal nodules in benign prostatic hyperplasia: morphologic and immunohistochemical characteristics. Prostate. 2014;74(14):1433–43.
pubmed: 25111578
doi: 10.1002/pros.22859
Mansour HM, Salama AAA, Abdel-Salam RM, Ahmed NA, Yassen NN, Zaki HF. The anti-inflammatory and anti-fibrotic effects of tadalafil in thioacetamide-induced liver fibrosis in rats. Can J Physiol Pharmacol. 2018;96(12):1308–17.
pubmed: 30398909
doi: 10.1139/cjpp-2018-0338
Mansour SM, El-Abhar HS, Soubh AA. MiR-200a inversely correlates with hedgehog and TGF-beta canonical/non-canonical trajectories to orchestrate the anti-fibrotic effect of Tadalafil in a bleomycin-induced pulmonary fibrosis model. Inflammopharmacology. 2021;29(1):167–82.
pubmed: 32914382
doi: 10.1007/s10787-020-00748-w
Cochetti G, Poli G, Guelfi G, Boni A, Egidi MG, Mearini E. Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role. Onco Targets Ther. 2016;9:7545–53.
pubmed: 28008272
pmcid: 5167485
doi: 10.2147/OTT.S119027
Bartel DP. Metazoan MicroRNAs. Cell. 2018;173(1):20–51.
pubmed: 29570994
pmcid: 6091663
doi: 10.1016/j.cell.2018.03.006
Greco F, Inferrera A, La Rocca R, Navarra M, Casciaro M, Grosso G, Gangemi S, Ficarra V, Mirone V. The potential role of MicroRNAs as biomarkers in Benign Prostatic Hyperplasia: a systematic review and Meta-analysis. Eur Urol Focus. 2019;5(3):497–507.
pubmed: 29398458
doi: 10.1016/j.euf.2018.01.008
Saiganesh S, Saathvika R, Arumugam B, Vishal M, Udhaya V, Ilangovan R, Selvamurugan N. TGF-beta1-stimulation of matrix metalloproteinase-13 expression by down-regulation of miR-203a-5p in rat osteoblasts. Int J Biol Macromol. 2019;132:541–9.
pubmed: 30951775
doi: 10.1016/j.ijbiomac.2019.04.003
Gutkoska J, LaRocco M, Ramirez-Medina E, de Los Santos T, Lawrence P. Host microRNA-203a is antagonistic to the progression of foot-and-mouth disease virus infection. Virology. 2017;504:52–62.
pubmed: 28152384
doi: 10.1016/j.virol.2017.01.019
Zhang Y, Wang F, Yu Y. LncRNA HOXD-AS1 promotes oral squamous cell carcinoma by sponging miR-203a-5p. Oral Dis. 2023;29(4):1505–12.
pubmed: 35152529
doi: 10.1111/odi.14152
Giacomini A, Grillo E, Rezzola S, Ribatti D, Rusnati M, Ronca R, Presta M. The FGF/FGFR system in the physiopathology of the prostate gland. Physiol Rev. 2021;101(2):569–610.
pubmed: 32730114
doi: 10.1152/physrev.00005.2020
Wang S, Lin H, Zhao T, Huang S, Fernig DG, Xu N, Wu F, Zhou M, Jiang C, Tian H. Expression and purification of an FGF9 fusion protein in E. Coli, and the effects of the FGF9 subfamily on human hepatocellular carcinoma cell proliferation and migration. Appl Microbiol Biotechnol. 2017;101(21):7823–35.
pubmed: 28921304
doi: 10.1007/s00253-017-8468-1
Chen L, Wang YY, Li D, Wang C, Wang SY, Shao SH, Zhu ZY, Zhao J, Zhang Y, Ruan Y, et al. LMO2 upregulation due to AR deactivation in cancer-associated fibroblasts induces non-cell-autonomous growth of prostate cancer after androgen deprivation. Cancer Lett. 2021;503:138–50.
pubmed: 33503448
doi: 10.1016/j.canlet.2021.01.017
Yang BY, Jiang CY, Dai CY, Zhao RZ, Wang XJ, Zhu YP, Qian YX, Yin FL, Fu XY, Jing YF, et al. 5-ARI induces autophagy of prostate epithelial cells through suppressing IGF-1 expression in prostate fibroblasts. Cell Prolif. 2019;52(3):e12590.
pubmed: 30883989
pmcid: 6536403
doi: 10.1111/cpr.12590
Zhang Y, Zhao J, Ding M, Su Y, Cui D, Jiang C, Zhao S, Jia G, Wang X, Ruan Y, et al. Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis. J Exp Clin Cancer Res. 2020;39(1):282.
pubmed: 33317606
pmcid: 7734763
doi: 10.1186/s13046-020-01761-1
Gregory KJ, Morin SM, Kubosiak A, Ser-Dolansky J, Schalet BJ, Jerry DJ, Schneider SS. The use of patient-derived breast tissue explants to study macrophage polarization and the effects of environmental chemical exposure. Immunol Cell Biol. 2020;98(10):883–96.
pubmed: 32713010
pmcid: 7754397
doi: 10.1111/imcb.12381
Joseph DB, Henry GH, Malewska A, Reese JC, Mauck RJ, Gahan JC, Hutchinson RC, Malladi VS, Roehrborn CG, Vezina CM, et al. Single-cell analysis of mouse and human prostate reveals novel fibroblasts with specialized distribution and microenvironment interactions. J Pathol. 2021;255(2):141–54.
pubmed: 34173975
pmcid: 8429220
doi: 10.1002/path.5751
Zenzmaier C, Sampson N, Pernkopf D, Plas E, Untergasser G, Berger P. Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia. Endocrinology. 2010;151(8):3975–84.
pubmed: 20555034
doi: 10.1210/en.2009-1411
Untergasser G, Gander R, Lilg C, Lepperdinger G, Plas E, Berger P. Profiling molecular targets of TGF-beta1 in prostate fibroblast-to-myofibroblast transdifferentiation. Mech Ageing Dev. 2005;126(1):59–69.
pubmed: 15610763
doi: 10.1016/j.mad.2004.09.023
Walker EJ, Heydet D, Veldre T, Ghildyal R. Transcriptomic changes during TGF-beta-mediated differentiation of airway fibroblasts to myofibroblasts. Sci Rep. 2019;9(1):20377.
pubmed: 31889146
pmcid: 6937312
doi: 10.1038/s41598-019-56955-1
Xiang P, Du Z, Wang M, Liu D, Yan W, Hao Y, Liu Y, Guan D, Ping H. RNA sequencing and integrative analysis reveal pathways and hub genes associated with TGFbeta1 stimulation on prostatic stromal cells. Front Genet. 2022;13:919103.
pubmed: 36035183
pmcid: 9412917
doi: 10.3389/fgene.2022.919103
Giri D, Ropiquet F, Ittmann M. FGF9 is an autocrine and paracrine prostatic growth factor expressed by prostatic stromal cells. J Cell Physiol. 1999;180(1):53–60.
pubmed: 10362017
doi: 10.1002/(SICI)1097-4652(199907)180:1<53::AID-JCP6>3.0.CO;2-P
Wei X, Zhang L, Zhou Z, Kwon OJ, Zhang Y, Nguyen H, Dumpit R, True L, Nelson P, Dong B, et al. Spatially restricted stromal wnt signaling restrains prostate epithelial progenitor growth through Direct and Indirect mechanisms. Cell Stem Cell. 2019;24(5):753–e768756.
pubmed: 30982770
pmcid: 6548441
doi: 10.1016/j.stem.2019.03.010
Bushman WA, Jerde TJ. The role of prostate inflammation and fibrosis in lower urinary tract symptoms. Am J Physiol Ren Physiol. 2016;311(4):F817–21.
doi: 10.1152/ajprenal.00602.2015
Rodriguez-Nieves JA, Macoska JA. Prostatic fibrosis, lower urinary tract symptoms, and BPH. Nat Rev Urol. 2013;10(9):546–50.
pubmed: 23857178
pmcid: 5625295
doi: 10.1038/nrurol.2013.149
AbdelRazek M, Abolyosr A, Mhammed O, Fathi A, Talaat M, Hassan A. Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. World J Urol. 2022;40(8):2063–70.
pubmed: 35773357
pmcid: 9279271
doi: 10.1007/s00345-022-04071-7
Bisegna C, Gravina GL, Pierconti F, Martini M, Larocca L, Rossi P, Grimaldi P, Dolci S, Di Stasi S, Jannini EA. Regulation of PDE5 expression in normal prostate, benign prostatic hyperplasia, and adenocarcinoma. Andrology. 2020;8(2):427–33.
pubmed: 31433119
doi: 10.1111/andr.12695
Morelli A, Comeglio P, Filippi S, Sarchielli E, Vignozzi L, Maneschi E, Cellai I, Gacci M, Lenzi A, Vannelli GB, et al. Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit. Prostate. 2013;73(4):428–41.
pubmed: 22996758
doi: 10.1002/pros.22584
Sancer O, Kosar PA, Tefebasi MY, Ergun O, Demir M, Kosar A. Determination of miRNA expression profile in patients with prostate cancer and benign prostate hyperplasia. Turk J Med Sci. 2022;52(3):788–95.
pubmed: 36326314
pmcid: 10390105
doi: 10.55730/1300-0144.5374
Zhou L, Li Y, Li J, Yao H, Huang J, Li C, Wang L. Decoding ceRNA regulatory network and autophagy-related genes in benign prostatic hyperplasia. Int J Biol Macromol. 2023;225:997–1009.
pubmed: 36403772
doi: 10.1016/j.ijbiomac.2022.11.162
Yang H, Fang F, Chang R, Yang L. MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor beta receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology. 2013;58(1):205–17.
pubmed: 23401231
doi: 10.1002/hep.26315
Wang R, Sun Y, Yu W, Yan Y, Qiao M, Jiang R, Guan W, Wang L. Downregulation of miRNA-214 in cancer-associated fibroblasts contributes to migration and invasion of gastric cancer cells through targeting FGF9 and inducing EMT. J Exp Clin Cancer Res. 2019;38(1):20.
pubmed: 30646925
pmcid: 6334467
doi: 10.1186/s13046-018-0995-9
Ishioka K, Yasuda H, Hamamoto J, Terai H, Emoto K, Kim TJ, Hirose S, Kamatani T, Mimaki S, Arai D, et al. Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. Cancer Res. 2021;81(14):3916–29.
pubmed: 34083250
doi: 10.1158/0008-5472.CAN-20-4048
Huang CW, Lu SY, Huang TC, Huang BM, Sun HS, Yang SH, Chuang JI, Hsueh YY, Wu YT, Wu CC. FGF9 induces functional differentiation to Schwann cells from human adipose derived stem cells. Theranostics. 2020;10(6):2817–31.
pubmed: 32194837
pmcid: 7052907
doi: 10.7150/thno.38553
Huang Y, Jin C, Hamana T, Liu J, Wang C, An L, McKeehan WL, Wang F. Overexpression of FGF9 in prostate epithelial cells augments reactive stroma formation and promotes prostate cancer progression. Int J Biol Sci. 2015;11(8):948–60.
pubmed: 26157349
pmcid: 4495412
doi: 10.7150/ijbs.12468